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The skin graft is a surgical technique commonly used in the reconstructive surgery of the limbs, in order to repair skin loss, as well
as to repair the donor area of the flaps and cover the dermal substitutes after engraftment. The unavoidable side effect of this
technique consists of unaesthetic scars. In order to achieve the healing of posttraumatic ulcers by means of tissue regeneration
and to avoid excessive scarring, a new innovative technology based on the application of autologous micrografts, obtained by
Rigenera technology, was reported. This technology was able to induce tissue repair by highly viable skin micrografts of 80
micron size achieved by a mechanical disaggregation method. The specific cell population of these micrografts includes
progenitor cells, which in association with the fragment of the Extracellular Matrix (ECM) and growth factors derived by
patients’ own tissue initiate biological processes of regeneration enhancing the wound healing process. We have used this
technique in 70 cases of traumatic wounds of the lower and upper limbs, characterized by extensive loss of skin substance and
soft tissue. In all cases, we have applied the Rigenera protocol using skin micrografts, achieving in 69 cases the complete healing
of wounds in a period between 35 and 84 days. For each patient, the reconstructive outcome was evaluated weekly to assess the
efficacy of this technique and any arising complication. A visual analogue scale (VAS) was administered to assess the amount of
pain felt after the micrografts’ application, whereas we evaluated the scars according to the Vancouver scale and the wound
prognosis according to Wound Bed Score. We have thus been able to demonstrate that Rigenera procedure is very effective in
stimulating skin regeneration, while reducing the outcome scar.
1. Introduction
Complex injuries of the limbs, causing crushing and loss of
skin and soft tissue, occur frequently due to common inju-
ries, both domestic and at work. The aim of surgical treat-
ment is the morphological and functional reconstruction,
allowing the recovery of the shape of the injured limbs and,
at the same time, the reconstruction of its normal protective
well-padded and sensitive skin which has specific properties
for giving the limbs their principal functions: gait ability
and grasp ability. Unfortunately, the regeneration of a spe-
cialized tissue (i.e., skin) requires the restoring of the entire
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histological hierarchy. Usually, when the injury causes wide
and deep loss of the skin and soft tissue, with bone fracture
exposed, in order to achieve a functional reconstruction,
using free flaps is preferable [1–3], while a useful option is
covering the wound with a dermal template [4, 5]. However,
in performing of all these techniques, skin grafts taken from
the thighs/buttocks to directly repair the injury (or the donor
site of the flap) are always essential, as well as the use of der-
mal substitute after its engraftment, often causing unsightly
scars both at the donor and recipient site of skin grafts.
To avoid unaesthetic scars, considered an inevitable side
effect of this technique, and to allow at the same time tissue
regeneration of the injured site, a new innovative technology
based on the application of autologous micrografts obtained
by Rigenera® technology, able to induce tissue repair by
highly viable skin micrografts achieved by a mechanical dis-
aggregation method [6–8], was recently reported. A small
piece of dermal/connective tissue may improve tissue repair
of complex wounds [9–11] or hypertrophic scars [12]. At
first, micrograft technology was applied in oral-maxillofacial
surgery where micrografts derived from the human dental
pulp or periosteum were used for periodontal regeneration,
bone regeneration of atrophic maxilla, and alveolar socket
preservation [13–16]. In the last few years, micrograft tech-
nology was applied in plastic and reconstructive surgery
where micrografts derived from the cartilage were used for
treatment of osteochondral lesion of the nose [17] and for
enrichment of adipose tissue from human lipoaspirates [18].
Based on these considerations, the purpose of this obser-
vational study was to evaluate the efficacy of micrografts in
the treatment of posttraumatic skin defects. For this reason,
we have used this approach in the treatment of the post-
traumatic wounds of the limbs, with excellent results in terms
of clinical outcomes and demonstration of the regenerative
capacity of this method by means of the tissue characte-
rization [7].
2. Patients and Methods
2.1. Patients. From 2015 to February 2017 in four Italian
Plastic and Reconstructive Units, we treated 70 patients, 38
females and 32 males with a mean age of 53 years (range 34-
74 years), affected by chronic posttraumatic leg ulcer applying
Rigenera protocol. All patients signed written consent to
participate according to the Declaration of Helsinki. Ethics
Committee approved the study (protocol N.2017-0274OR).
Clinical Trial of the study is found inhttps://clinicaltrials.gov/
ct2/show/NCT04030832. 24 patients suffer from bone expo-
sure through chronic posttraumatic ulcer or surgical wound
dehiscence with a mean bone exposed surface of 2 cm2, and
12 patients suffer from tendon exposure through chronic
posttraumatic ulcer or surgical wound dehiscence. In three
cases, we combined the use of Rigenera procedure with the
Integra® dermal regeneration template. In one of these three
patients, the Rigenera protocol was used to treat the donor site
of a free flap applying the Rigenera® biocomplex over the
neoderma created by Integra®. The mean time between
trauma and Rigenera treatment was 7 weeks (range 2-18
weeks) (Table 1). All patients provided informed consent at
the study protocol conformed to the ethical guidelines of the
1975 Declaration of Helsinki. The primary diagnosis and ini-
tial operative procedures leading to wound dehiscence are
listed in Table 1. We also reported the correlated diseases
affecting the patients. After an average 1-year follow-up, the
evaluation of wound closure was accomplished.











Age 53 years 34-74 years
Underlying disease
None 49 (70%)









Wound dehiscence 18 (26%)
Posttraumatic ulcer 32 (45%)
Metabolic ulcer 18 (26%)
Burn 2 (3%)







Before procedure 8 (11%)






70 (100%) 6 days 6 days
Time of complete
healing
48 days 35-84 days
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2.2. Surgical Procedure. All cases reported in this study were
treated by means of the Rigenera protocol after surgical or
enzymatic ulcer’s debridement and after wound infection
resolution probe by culture exam. The Rigenera® technology
is based on the use of the Rigenera machine and Rigenera-
cons (Human Brain Wave, Turin, Italy), a biological disrup-
tor able to disaggregate small pieces of human connective
tissues and select a specific cell population including progen-
itor cells, on the basis of cellular size. These progenitor cells,
in association with the fragment of the Extracellular Matrix
(ECM) and growth factors derived by starting tissue, create
autologous micrografts ready for use, which can be applied
on the injured area alone or in combination with different
biological scaffolds, such as collagen. This protocol consists
of different steps: (1) collection of a skin tissue sample
of 1 cm × 1 cm from a hide donor site with respect to the
recipient site (expansion ratio 1 : 10) (Figure 1(a)) (each
skin sample is divided into fragments of about 2mm2 each);
(2) the fragments are positioned in two separated single-use
capsules, below the rotating system of helical blades, resting
on the filter placed on the bottom of the capsule (disaggrega-
tion of tissue for two minutes by Rigeneracons through the
addition of 3ml of sterile saline solution) (Figure 1(b)); (3)
collection of 2.5ml of autologous micrografts obtained after
the disaggregation in a sterile solution (Figure 1(c)) from
each capsule; (4) injection of 2.5ml of micrograft solution
on an equine collagen sponge to create a regenerative bio-
complex (Figure 1(d)); (5) injection of 2.5ml of micrograft
solution into the site of injury by perilesional infiltrations
and placement of the biocomplex over the ulcer taking care
that the seeded surface of the sponges was in contact with
the wound floor (Figures 1(e) and 1(f)); and (6) secondary
medication by means of paraffin gauge tie over (Figure 1(g)).
In our patients, we collected small pieces of tissue by
inguinal fold after local anaesthesia. Following the applica-
tion of micrografts, all patients received for 6 days oral
penicillin therapy. We performed the first dressing after
4 days without paraffin gauge removal and a second dress-
ing after 3 days with paraffin gauge change and subjected
the patients to weekly controls to evaluate the progression
of wound healing. After complete healing on the treated
site, moisture oil was gently applied, and after one month,
the patient starts tissue massage and follow-up visit was
delayed in a month’s time.
2.3. Clinical, Pain, and Scar Evaluation. For each patient, the
surface of the wounds at days 4 and 7 and every week up to
complete healing has been measured and each wound was
assessed for contraction. Surfaces were followed by tracing
the wound edges on the computer with digital pictures.
Wound contraction was measured by computer planimetry,
expressed in percentage of reduction of the original wound
area. At each follow-up visit, we record side effects and com-
plications, and a visual analogue scale (VAS) was adminis-
tered to assess the amount of pain felt after the micrografts’
application. The pain VAS is in fact self-completed by the
respondent who is asked to place a line perpendicular to
the VAS line at the point representing its pain intensity.
The number indicated by the respondent on the scale is
recorded, and the scores range from 0 to 10, where 0 indi-
cates pain absence and 10 severe pain [19]. Functional and
aesthetic outcome was assessed using the Vancouver scale
VSS [20] (height, pliability, vascularization, and pigmenta-
tion of scars) and Wound Bed Score [21] (healing time,
eschar, granulation tissue, exudate, dermatitis, fibrosis,
and wound bed) two months (T0) and 12 months (T1)
after reepithelialisation.
2.4. Statistical Analysis. Application of the Shapiro-Wilk test
showed data had no normal distribution; accordingly, all
statistical analyses were carried out according to a nonpara-
metric approach. To investigate the effectiveness of the
Rigenera® technology, the total VSS and WBS score absolute
variations between T0 and T1 were calculated, as well as the
corresponding median values and their 95% Confidence
Interval (95% CI). Median values were then compared using
the Wilcoxon signed-rank test. Further, the percentage vari-
ation between T0 and T1 was calculated for each item of
the VSS and WBS scale, and differences in each item of the
two scales between T0 and T1 were investigated by means
of Friedman’s test.
All data were statistically analyzed using a one-way
ANOVA test. The threshold for statistical significance was
set at p values < 0.05. Repeatability is represented as a stan-
dard deviation to calculate the differences between measure-
ments using SPSS 16.0 software (SPSS Inc., Chicago, IL,
USA) for assessment.
3. Results
70 patients admitted to our Plastic and Reconstructive Unit
were enrolled in this study. Follow-up of 90% was achieved at
1 year. Patient number 6 was removed from the study after
developing Stevens-Johnson syndrome after administration
of the second antibiotics. The mean age was 53 years (range
34-74 years), with 26 men (37%) and 44 women (63%). One
hundred percent of wounds were located on the lower limb.
Patientsandwounddescriptions are shown inTable1.Theori-
gin of the soft tissue defect was open fracture in 24 patients
(34%) and full-thickness skin wounds with tendon exposure
in 12 patients (17%). In addition, Rigenera protocol was used
in combination with Integra® dermal regeneration in 3
patients (4%). The mechanism of injury included trauma in
the majority of cases (45%) and wound dehiscence (26%) and
metabolic ulcer (26%) in the remaining cases. The mean time
between trauma and the Rigenera treatment was 7 weeks
(range 2-18 weeks). In all the other patients, we observed, on
average, a complete healing of the ulcer with bone or tendon
coverage in 48 days after the micrografts’ application, with a
range variable between 35 and 84 days. In all cases, the micro-
grafts were applied only once; no side effect or complication
was detected. In case numbers 7, 8, and 14, the micrografts
were associated to Integra®. In cases 7 and 8, it was
employed as secondary dressing; in these patients, the
complete healing was achieved without a secondary surgi-
cal procedure of skin grafting. In case 14, the micrografts
were put over the dermal substitute 30 days after its
engraftments in order to achieve complete
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reepithelialisation without the secondary procedure of skin
graft. In these three cases, wound healing was obtained
after, respectively, 35, 42, and 35 days. At day 0, surfaces
of every wound were about 14 cm2 (range 7-28 cm2). At
day 7, mean surfaces were 11.6 cm2 (standard error of
the mean was ±2.3 cm2). At day 14, mean surfaces were
9.3 cm2 (standard error of the mean was ±1.6 cm2). At






Figure 1: (a) Intraoperative view of skin tissue sample collection from the groin area. (b) Intraoperative view of Rigeneracons filling with
2mm pieces obtained from the tissue sample. (c) Intraoperative view of collection of autologous micrografts obtained after the
disaggregation in a sterile solution. (d) Injection of 1ml of the micrograft solution on an equine collagen sponge. (e) Intraoperative view
of Rigenera biocomplex, consisting of collagen sponge and disaggregated tissue solution, put in the wound’s bed. (f) Intraoperative view of
perilesional injection of 1ml of micrograft solution. (g) Intraoperative view of tie over dressing over Rigenera biocomplex.
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the mean was ±2.1 cm2). At day 48, mean surfaces were
0 cm2 (standard error of the mean was ±1.3 cm2)
(Figure 2(a)). Moreover, we observed contraction of all
wounds after the complete closure. Wound contraction
percentage was significantly different from 20% at day 48
(standard error of the mean was 4%, p < 0:001) to 40%
at day 60 (standard error of the mean was 3.4%, p <
0:001) (Figure 2(b)). The mean preoperative VAS score
was 6 (ranging from 4 to 9); meanwhile, the mean VAS
score at the first follow-up visit was 3 (ranging from 2
to 5) (Table 2(a)). The Vancouver Scar Scale (VSS) was
used to evaluate functional and aesthetic characteristics
of lesions after 2-month (T0) and 12-month (T1) follow-
up as shown in Table 2(b). There was no statistical differ-
ence in sex, age, underlying disease, and size of the defect.
The VSS mean value was 2 (ranging from 0 to 4). The
VSS score showed a significant reduction at the T1
follow-up control visit (p < 0:05). The WBS mean value
was 15.4. The WBS score showed a significant reduction
at the T1 follow-up control visit (p < 0:05) (Table 2(c)).
Results concerning the single items of VSS and WBS scale
are summarized in Table 2. The scores showed a signifi-
cant reduction at the T1 (12 months) follow-up control






























2 Months 6 Months 12 Months
(b)
Figure 2: (a) Mean surfaces of the wound (cm2). Error bars are the standard error of the means. (b) Scar contraction. We observe contraction








(a) Results of VAS score
VAS score 6 (9-4) 3,4 (5-2) 1 (2-0) p < 0:05
(b) Results of Vancouver Scar Scale
Vascularity 2 0 p = 0:003
Pigmentation 0 0 p = 0:5
Pliability 1 1 p = 0:5
Height 2 1 p = 0:016
Total score 4,1 (6-2) 2,03 (4-0) p < 0:05
(c) Results of Wound Bed Score scale
Healing edges 0 1 2 p < 0:05
Black eschar 1 2 2 p = 0:5
Greatest wound 0 1 2 p = 0:5
Depth/granulation tissue 0 0 2 p < 0:05
Exudate amount 0 2 2 p < 0:05
Edema 1 1 2 p = 0:5
Periwound dermatitis 0 0 1 p = 0:5
Periwound callus/fibrosis 0 0 1 p = 0:5
Pink wound bed 0 0 1 p = 0:5
Total score 3 7 15 p < 0:05
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decreased by 12units (-85.7%) and the median VAS score
decreased by 9 units (-90%) while the median WBS
increased by 158% (Figures 3(a)–3(c)). The VSS and
VAS scores decreased after the 12-month follow-up, the
greatest reduction being observed in height, pliability,
and pigmentation. All scars were supple, with a normal
height and a normal pigmentation. The only difference
between T0 and T1 was about the vascularization and
height. The WBS score increased after the 12-month fol-
low-up, the greatest increase being observed in healing
edges, exudate amount, and depth/granulation tissue. We
have used this technique in 70 cases of chronic wounds
of the lower limbs, characterized by extensive loss of skin
substance and soft tissue. In particular, a more fast and
complete reepithelialisation with respect to the other
advanced dressings that were previously utilized in the
treatment of the traumatic wounds of the limbs has been







































Figure 3: Variation of Vancouver (a), VAS (b), and WBS (c) total scores (squares, medians; bars, first and third quartiles). The reduction of
the total score is significant (p < 0:05) in both cases.
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4. Discussion
The skin grafts are a surgical technique commonly used in
the reconstructive surgery of the limbs, in order to directly
repair skin loss, as well as to repair the donor area of the flaps
and cover the dermal substitutes after engraftment. The inev-
itable side effect of this technique consists of unaesthetic
scars. The autologous tissue grafts produce very evident scars
and are unable to stimulate tissue regeneration, because the
interruption of blood circulation leads to an extensive inner
cell death. This issue is related to the prevalence of scarring
on skin regeneration in the management of traumatic
wounds and is even more evident in patients affected by
chronic diseases who are highly exposed to the risk of delayed
healing of the injured tissue leading to a pathological inflam-
matory state and chronic wounds [22]. Researchers are trying
to find approaches able to reduce scarring after wound heal-
ing, stimulating at the same time tissue regeneration, by
(a) (b) (c)
Figure 4: (a) Preoperative view. Dorsal foot dehiscence without bone or tendon exposure. (b) Image of the initial skin regeneration at follow-
up visit 7 days after treatment. (c) Image of the initial skin regeneration at follow-up visit 30 days after treatment.
(a)
(b) (c)
Figure 5: (a) Preoperative view. Foot stump dehiscence with 2 cm2 of bone exposure after forefoot amputation. (b) Intraoperative view of
Rigenera biocomplex, consisting of collagen sponge and disaggregated tissue solution, put in the wound’s bed and perilesional injection of
1ml of micrograft solution. (c) Image of good skin regeneration at follow-up visit 6 months after complete reepithelialisation.
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means of tissue engineering methods. Tissue engineering
aims to regenerate tissues through the combined use of bio-
materials and biologic mediators such as stem cells and
growth factors in order to provide new tools for regenerative
medicine [23, 24]. The repair and regeneration of human tis-
sues is particularly difficult in skeletal reconstruction of large
bone defects caused by trauma, infection, or skeletal abnor-
malities, and given that regenerative ability of bone declines
with increasing age, the dramatic rise in the ageing popula-
tion worldwide determined an increasing need for innovative
approaches [25]. Many approaches can be used when the
normal process of tissue regeneration is impaired or simply
(a) (b)
(c) (d)
Figure 6: (a) Preoperative view. Ankle dehiscence without bone or tendon exposure. (b) Intraoperative view of Rigenera biocomplex,
consisting of collagen sponge and disaggregated tissue solution, put in the wound’s bed and perilesional injection of 1ml of micrograft
solution. (c) Image of the initial skin regeneration at follow-up visit 7 days after treatment. (d) Image of good skin regeneration at follow-
up visit 6 months after complete reepithelialisation.
(a) (b)
(c) (d)
Figure 7: (a) Preoperative view. Achilles tendon dehiscence without bone or tendon exposure. (b) Image of the initial skin regeneration at
follow-up visit 7 days after treatment. (c) Image of skin regeneration at follow-up visit 21 days after treatment. (d) Image of good skin
regeneration at follow-up visit 6 months after complete reepithelialisation.
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insufficient, such as grafting which includes autografts, allo-
grafts, xenografts, and biomaterial substitutes [26]. For the
safety of grafting procedure, the autologous grafts are prefer-
able to those homologous or heterologous grafts, and
although it prevents immunoreactions and infections, this
approach is limited due to additional surgical procedure on
the donor site and discomfort for the patient. Furthermore,
about the autologous grafts, the cell viability dramatically
decreases after collection from the donor site for vessel inter-
ruption by surgery with reduced feeding for the cells. The
Rigenera® technology represents a new approach for human
injured tissue regeneration, and when using this technology,
the patient is the donor and acceptor of calibrated and highly
viable micrografts containing progenitor cells positive for
mesenchymal stem cell markers able to induce tissue repair
[7, 11]. In vitro data on their characterization have reported
that micrografts display a mesenchymal phenotype and are
positive for typical markers such as CD73, CD90, CD105,
and CD117 and have showed their capability to differentiate
in osteocytes, chondrocytes, or adipocytes in appropriate
experimental conditions [13, 31]. Furthermore, the clinical
efficacy of these micrografts has been demonstrated both
in the healing of postoperative and posttraumatic wounds
[9–11, 27] and pathological scars [12]. In particular, a
more fast and complete reepithelialisation with respect to
the other advanced dressings that were previously utilized
in the treatment of the traumatic wounds of the limbs has
been observed, with excellent results in terms of clinical
efficacy and demonstration of the regenerative capacity of
this method [7, 8]. The micrografting concept was conceived
by Cicero Parker Meek and was based on the evidence that
skin grafts expanded many times were able to heal a wound
faster than the original-sized grafts [28]. Therefore, the best
way to achieve a good grafting performance is by increasing
the superficial area of the graft leading to a faster cellular
migration onto the wound and reducing cellular death of
the graft itself. Since then, the micrograft concept was applied
to many procedures [29, 30].
Rigenera technology is different from any of them
because it is able to generate a suspension of micron-sized
grafts (micrografts) which are applied with the help of a
syringe. The average size of the Rigenera-obtained micro-
grafts is 80μm, extremely smaller than any other technology
available on the market or ever described in literature. Lastly,
while performing the disaggregation, this technology allows
for a collection of only the smaller cells which also express
the mesenchymal stem cell markers, described as stem cell-
like or progenitor cells, which are accounted for a strong
regenerative effect [13, 31]. We have used this technology
in 70 cases of chronic wounds of the lower limbs, character-
ized by extensive loss of skin substance and soft tissue. Some
of these patients were affected by severe chronic diseases with
poor vascularization of the skin. In all cases, we have applied
the Rigenera protocol using skin micrografts, achieving in 69
cases the complete healing of wounds in a period between 35
and 84 days. Wound healing was characterized by complete
reepithelialisation with clinical and histological evidence of
a repair that occurred through a process of tissue regenera-
tion and low presence of scar at the injured area [7, 8]. The
regenerative efficacy of micrografts could arise from the pres-
ence of small particle-sized autografts characterized by a
large grafting surface, leading to an optimal cellular viability
and integrity, for minor nutritional needs of the cells. Partic-
ularly, the mechanical disaggregation of small pieces of
human connective tissues produces a suspension of autolo-
gous micrografts of 80μm size, ready for use, which can be
applied on the injured area alone or in combination with dif-
ferent biological scaffolds, such as collagen and hyaluronic
acid. The specific cell population of these micrografts
includes progenitor cells, which in association with the frag-
ment of the Extracellular Matrix (ECM) and growth factors
derived by starting tissue initiate biological processes of cell
proliferation and differentiation enhancing the wound heal-
ing process. This is the “micrograft theory” that may explain
the excellent reconstructive outcomes in the treatment of the
injured limbs applying autologous micrografts obtained by
the Rigenera® technology.
5. Conclusions
The autologous micrografts obtained by the Rigenera® tech-
nology are an innovative protocol that introduces a whole
new concept in regenerative surgery, allowing to repair severe
traumatic wounds of the limbs by complete reepithelialisa-
tion. The impressive clinical outcomes combined with the
laboratory tests on the tissue characterization demonstrate
that this technology is really able to stimulate skin regenera-
tion and probably it is the only one available today able to
ensure the healing of traumatic injuries through a real regen-
erative procedure. In addition, the minimum amount of skin
required to produce micrografts with the Rigeneracons in the
repair of wide traumatic wounds prevents scarring usually
produced by traditional techniques at the donor site.
Definitely, this innovative technology is not just a new
technique but a whole new concept in regenerative surgery.
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